

## Off-Label Systemic Therapies in AD

Drug	Estimated efficacy (% reduction in composite severity scores)	Dose range	Common or serious side effects	Monitoring required
Azathioprine <sup>a</sup>	26%–39%	Adult: 1–3 mg/kg/day Pediatric: 1–4 mg/kg/day	Hematologic abnormalities, malignancies, hepatosplenic lymphoma, CNS infections	CBC, CMP, thiopurine methyl- transferase
Cyclosporine <sup>a</sup>	53%–95%	Adult and pediatric: 2.5–5 mg/kg	Renal insufficiency, hypertension, and drug interactions	CBC, CMP, magnesium, uric acid, lipids, BP
Methotrexate <sup>a</sup>	42%	Adult: 7.5–25 mg/week Pediatric: 0.2–0.7 mg/kg/week	Hepatotoxicity, hematologic abnormalities, teratogenic effects, GI intolerance, nausea, fatigue	CBC, CMP
Mycophenolate <sup>a</sup>	Unknown	Adult: 1-1.5 g orally twice/day Pediatric: 30-50 mg/kg/day	GI, teratogenic effects	CBC, CMP
Steroids (Prednisone, Prednisolone) <sup>b</sup>	22%–49% <sup>c</sup>	Adult and pediatric: 0.5–1.0 mg/kg	Hypertension, glucose intolerance, gastritis, weight gain, decreased bone density, adrenal suppression, emotional lability, decreased linear growth (pediatric patients)	Potentially blood pressure monitoring, ophthalmologic examination, hypothalamic-pituitary-adrenal axis suppression testing, bone density evaluation (adults), growth velocity measurement (children)

School of Medicine Simpson EL, et al. *J Am Acad Dermatol*. 2017;77(4):623–633; Yu S, et al. *J Am Acad Dermatol*. 2018;78:733–740; Sidbury R, et al. *J Am Acad Dermatol*. 2014;71:327–349.

smhs.gwu.edu